Leukemia Research
Volume 28, Issue 3 , Pages 249-257 , March 2004

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature

  • Alexander W Hauswirth

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna, Austria
    • ,
  • Ingrid Simonitsch-Klupp

      Affiliations

    • Department of Clinical Pathology, University of Vienna, Vienna, Austria
    • ,
  • Martin Uffmann

      Affiliations

    • Department of Radiology, University of Vienna, Vienna, Austria
    • ,
  • Elisabeth Koller

      Affiliations

    • Medical Department for Hematology and Oncology, Hanusch-Hospital, Vienna, Austria
    • ,
  • Wolfgang R Sperr

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna, Austria
    • ,
  • Klaus Lechner

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna, Austria
    • ,
  • Peter Valent

      Affiliations

    • Department of Internal Medicine I, Division of Hematology and Hemostaseology, University of Vienna, Währinger Gürtel 18–20, A-1090 Vienna, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43-1-40400-5488/6085; fax: +43-1-402-69-30.

Received 28 February 2003 ,Accepted 12 July 2003.

References 

  1. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology. 1979;3:349–365
  2. Parwaresch MR, Horny H-P, Lennert K. Tissue mast cells in health and disease. Pathol. Res. Pract. 1985;179:439–461
  3. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J. Invest. Dermatol. 1991;96:2S–4S
  4. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wschr. 1996;108:385–397
  5. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine. 1988;67:345–368
  6. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade’s clinical experience at the Brigham and Women’s Hospital. J. Invest. Dermatol. 1991;96:5S–13S
  7. Caplan RM. The natural course of urticaria pigmentosa. Arch. Dermatol. 1963;87:146–157
  8. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 1995;92:10560–10564
  9. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al.  Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 1996;12:312–314
  10. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al.  Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. U.S.A. 1999;96:1609–1614
  11. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al.  Mutation analysis of c-kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 2001;113:357–364
  12. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 2000;28:140–147
  13. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, et al.  Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukemia. Mol. Pathol. 2000;53:188–193
  14. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood. 2002;100:661–665
  15. Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cervero C, Lopez A, et al.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91:2731–2736
  16. Escribano L, Dı́az-Agustı́n B, Bellas C, Navalón R, Nuñez R, Sperr WR, et al.  Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk. Res. 2001;25:563–570
  17. Mican JM, Di-Bisceglie AM, Fong TL, Travis WD, Kleiner DE, Baker B, et al.  Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology. 1995;22:1163–1170
  18. Kyriakou D, Kouroumalis E, Konsolas J, Oekonomaki H, Tzardi M, Kanavaros P, et al.  Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis—report of four cases. Am. J. Gastroenterol. 1998;93:106–108
  19. Rafii M, Firooznia H, Golimbu C, Balthazar E. Pathologic fracture in systemic mastocytosis: radiographic spectrum and review of the literature. Clin. Orthop. 1983;180:260–267
  20. Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am. J. Med. 1991;91:612–624
  21. Travis WD, Li CY, Yam LT, Bergstralh EJ, Swee RG. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 1988;62:965–972
  22. Horny H-P, Ruck M, Wehrmann M, Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br. J. Haematol. 1990;76:186–193
  23. Sperr WR, Horny H-P, Lechner K, Valent P. Clinical and biologic diversity of leukemias occuring in patients with mastocytosis. Leuk. Lymphoma. 2000;37:473–486
  24. Escribano L, Orfao A, Villarrubia J, Martin F, Madruga JI, Cuevas M, et al.  Sequential immunophenotypic analysis of mast cells in a case of mast cell disease evolving to a mast cell leukamia. Cytometry. 1997;30:98–102
  25. Valent P, Horny H-P, Escribano L, Longley BJ, Li CY, Schwartz LB, et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 2001;25:603–625
  26. Worobec AS, Kirshenbaum AS, Schwartz LB, Metcalfe DD. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk. Lymphoma. 1996;22:501–508
  27. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, et al.  Response to interferon alfa-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 1992;326:619–623
  28. Lehmann T, Beyeler C, Lammle B, Hunziker T, Vock P, Olah AJ, et al.  Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-26. Br. J. Rheumatol. 1996;35:898–900
  29. Jost E, Michaux L, Vanden Abeele M, Boland B, Latinne D, Godfraind C. Complex karyotype and absence of mutation in the c-kit receptor in aggressive mastocytosis presenting with pelvic osteolysis, eosinophilia and brain damage. Ann. Hematol. 2001;80:302–307
  30. Weide R, Ehlenz K, Lorenz W, Walthers E, Klausmann M, Pfluger KH. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann. Hematol. 1996;72:41–43
  31. Butterfield JH. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol. 1998;138:489–495
  32. Fiehn C, Prummer O, Gallati H, Heilig B, Hunstein W. Treatment of systemic mastocytosis with interferon-gamma: failure after appearance of anti-IFN-gamma antibodies. Eur. J. Clin. Invest. 1995;25:615–618
  33. Pulik M, Lionnet F, Petit A, Genet P, Gaulier A. Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia. Am. J. Hematol. 1994;47:66
  34. Chosidow O, Becherel PA, Piette JC, Arock M, Debre P, Frances C. Tripe palms associated with systemic mastocytosis: the role of transforming growth factor-alpha and efficacy of interferon-alfa. Br. J. Dermatol. 1998;138:698–703
  35. Krahl J, Baldauf P, Stoermer D. Systemische konnatale Mastozytose mit universeller Hautbeteiligung. Hautarzt. 1999;50:893–896
  36. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N. Engl. J. Med. 2001;344:307–309
  37. Delaporte E, Pierard E, Wolters BG, Desreumaux P, Janin A, Cortot A, et al.  Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br. J. Dermatol. 1995;132:479–482
  38. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny H-P, et al.  Aggressive systemic mastocytosis: current treatment options and proposed response criteria. Leuk Res. 2003;27:635–641
  39. Horny H-P, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, et al.  Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 1998;22:1132–1140
  40. Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny H-P, et al.  Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 2001;25:529–536
  41. Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Van der Zwan JK, et al.  Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J. Clin. Immunol. 1994;14:190–204
  42. Sperr WR, Jordan JH, Fiegl M, Escribano L, Dirnhofer S, Semper H, et al.  Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int. Arch. Allergy Immunol. 2002;128:136–141
  43. Travis WD, Li CY, Hoagland HC, Travis LB, Banks PM. Mast cell leukemia: report of a case and review of the literature. Mayo Clin. Proc. 1986;61:957–966
  44. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, et al.  The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Invest. 1995;96:2702–2710
  45. Schernthaner G, Spanblöchl E, Sperr WR, Sillaber C, Semper H, Jurecka W, et al.  Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitors in a patient with systemic mastocytosis. Ann. Hematol. 2000;79:660–666
  46. Galli SJ. Biology of disease—new insights into ‘the riddle of the mast cells’: microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab. Invest. 1990;62:5–33
  47. Födinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H, et al.  Origin of human mast cells: development from transplanted hemopoietic stem cells after allogeneic bone marrow transplantation. Blood. 1994;84:2954–2959
  48. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J. Invest. Dermatol. 1991;96:2S–4S
  49. Worobec AS. Treatment of systemic mast cell disorders. Hematol. Oncol. N. Am. 2000;14:659–687
  50. Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J. Clin. Invest. 1987;99:1721–1728

PII: S0145-2126(03)00259-5

doi: 10.1016/S0145-2126(03)00259-5

Leukemia Research
Volume 28, Issue 3 , Pages 249-257 , March 2004

Article Tools

* Image Usage & Resolution